Mono Pharmacare (NSE:MONOPHARMA) Total Equity: ₹313 Mil (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:MONOPHARMA Mono Pharmacare Ltd NSE:MONOPHARMA
9 GF Score
Price ₹10.75
! 6 Warning Signs
View Full Analysis

What is Mono Pharmacare Total Equity?

Mono Pharmacare NSE:MONOPHARMA 9 Total Equity is ₹313 Mil as of Sep. 2025. GuruFocus rates NSE:MONOPHARMA with a GF Score™ of 9/100. The stock has 6 warning signs investors should review.

Mono Pharmacare's total equity for the quarter that ended in Sep. 2025 was ₹313 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Mono Pharmacare Total Equity Historical Data

* Premium members only.

The historical data trend for Mono Pharmacare's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mono Pharmacare Total Equity Chart

Mono Pharmacare Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
Total Equity
36.96 42.76 133.99 281.28 312.34

Mono Pharmacare Semi-Annual Data
Mar21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
Total Equity Get a 7-Day Free Trial Premium Member Only 275.53 281.28 304.29 312.34 312.56
NSE:MONOPHARMA
9GF Score
Mono Pharmacare Ltd NSE:MONOPHARMA
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mono Pharmacare Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Mono Pharmacare's Total Equity for the fiscal year that ended in Mar. 2025 is calculated as

Total Equity=Total Assets(Q: Mar. 2025 )-Total Liabilities(Q: Mar. 2025 )
=1100.55-788.206
=312

Mono Pharmacare's Total Equity for the quarter that ended in Sep. 2025 is calculated as

Total Equity=Total Assets(Q: Sep. 2025 )-Total Liabilities(Q: Sep. 2025 )
=1193.37-880.808
=313

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of ₹313 Mil mean?
Mono Pharmacare (NSE:MONOPHARMA) has a Total Equity of ₹313 Mil as of Sep. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Mono Pharmacare and its competitors.
Is Mono Pharmacare's Total Equity too high?
Mono Pharmacare's current Total Equity is ₹313 Mil. Overall, Mono Pharmacare has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Mono Pharmacare's Total Equity compare to competitors?
Mono Pharmacare's Total Equity of ₹313 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Healthcare Providers & Services company?
A good Total Equity depends on the Healthcare Providers & Services industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Mono Pharmacare and its competitors. Mono Pharmacare's current Total Equity is ₹313 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mono Pharmacare stock overvalued right now?
Mono Pharmacare (NSE:MONOPHARMA) has a current Total Equity of ₹313 Mil. The current Total Equity is ₹313 Mil. Mono Pharmacare's overall GF Score™ is 9/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Mono Pharmacare (NSE:MONOPHARMA), the current Total Equity is ₹313 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mono Pharmacare Business Description

Address 1A, Krinkal Apartment, Opposite Mahalaxmi Temple, Paldi, Ahmedabad, GJ, IND, 380007
Mono Pharmacare Ltd distributes a broad range of pharmaceutical products across India. Its portfolio includes antibiotics, antifungal medicines, cough and cold remedies, antacids, analgesics, nutraceuticals, skincare, antiseptics, cardiac and diabetic drugs, and cosmetic items. The company operates through contract manufacturing, sourcing products from various manufacturers and supplying them to healthcare providers and pharmacies. Revenue is generated through the sales and distribution of these pharmaceutical and healthcare products in the Indian market.
9GF Score

Get the complete analysis for NSE:MONOPHARMA

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹10.75
Price